# THE MULTIPLE LOCI CONTROL OF HUMAN IA ALLOANTIGENS

> **NIH NIH R01** · ROSWELL PARK CANCER INSTITUTE · 1988 · $132,116

## Abstract

Our proposed research will be focused on two objectives:  The first is to
fill existing gaps in the immunogenetic analysis of the HLA-D system and to
reach a more detailed knowledge of the polymorphism of DR, DQ and DR
subregions.  This study will be done at the protein level by the
immunochemical approach we have developed.  The second is to investigate
the role that different Class II products play in the generation of
HLA-associated diseases.  By radioimmunoassay typing, several newly
discovered markers, located on different Class II molecules, will be tested
for their association with coeliac disease, insulin-dependent diabetes
mellitus and rheumatoid arthritis.  For the coeliac disease, an analysis at
the DNA level will be performed with he aim of defining the precise
disease-associated sequence site.

Specifically, we will direct our effort toward the following projects:

1) Analysis of HLA Class II molecules controlled by different DR haplotypes
and of those expressed on mouse cells transfected with a single DR Beta
gene by immunospecifically isolating the Class II molecules and analyzing
their structural features by two-dimensional peptide mapping.

2) Subunit assignment of DQ alloantigenic determinants by serologically
analyzing the Class II molecules expressed on mouse cells transfected
either with DQw2 Alpha and DQw3 Beta genes or with DQw2 Beta and DQw3 Alpha
genes.

3) Serological detection of HLA-DP allospecificity by isolating DP
molecules from mouse cells transfected with DP Alpha and Beta genes and
testing their reactivity with anti-Class II alloantisera by the direct
binding assay.

4) HLA-disease association studies by typing patients with coeliac disease,
insulin-dependent diabetes mellitus and rheumatoid arthritis for newly
found "haplotype-discriminating specificities".

5) Molecular genetic study of coeliac disease by sequencing the Beta domain
of DQw2 molecules expressed on cells of B-cell lines established from
DR3-homozygous coeliac disease patients by using the primer extension
method.

## Key facts

- **NIH application ID:** 3129806
- **Project number:** 5R01AI020251-06
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE
- **Principal Investigator:** NOBUYUKI TANIGAKI
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $132,116
- **Award type:** 5
- **Project period:** 1983-07-01 → 1990-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3129806

## Citation

> US National Institutes of Health, RePORTER application 3129806, THE MULTIPLE LOCI CONTROL OF HUMAN IA ALLOANTIGENS (5R01AI020251-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3129806. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*